7 products found

Veracyte, Inc. products

Afirma - Genomic Sequencing Classifier - Thyroid Cancer

Reducing Unnecessary Surgeries and Informing Treatment Decisions in Thyroid Cancer Diagnosis. The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) provide physicians with a comprehensive solution for a complex landscape in thyroid cancer diagnosis and individualization of care. The combined offering enables physicians to answer multiple clinical questions for their thyroid patients using a single, minimally invasive fine needle aspiration (FNA) sample.

Bladder Genomic Test

Revealing cancer molecular subtype to inform treatment decisions. Decipher Bladder is a genomic test that measures the molecular profile of bladder cancer using gene expression analysis from transurethral resected bladder tumor specimens. The test was developed for bladder cancer patients with high-grade non-muscle-invasive disease who are being considered for treatment and patients with muscle-invasive disease who face the question of immediate cystectomy or systemic treatment in the neoadjuvant setting prior to cystectomy (NAC). Decipher Bladder reports the molecular subtype of the tumor specimen as Luminal or Non-Luminal (Luminal Infiltrated, Basal, Basal Claudin-Low or Neuroendocrine-like), with each subtype having distinct biological composition, clinical behavior and predicted benefit from NAC.

Prosigna - Breast Cancer Prognostic Gene Signature Assay

Using prognostic information to inform next steps in patient care. The Prosigna Breast Cancer Prognostic Gene Signature Assay uses advanced genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease. The test analyzes the activity of 50 genes known as the PAM50 gene signature, along with clinical-pathological features, and can provide a hormone-receptor positive early breast cancer patient and her physician with a prognostic score indicating the probability of cancer recurrence during the next 10 years. Outside of the United States, it is also utilized to provide PAM50 molecular subtype information.

Percepta - Lung Cancer Diagnostics

Avoiding unnecessary procedures, speeding time to diagnosis and appropriate treatment. Lung cancer is the leading cancer killer worldwide, causing approximately 1.8 million deaths each year. Veracyte’s comprehensive portfolio of lung cancer genomic tests is designed to improve outcomes for patients at each step of their journey, with an ultimate goal of saving more lives.

LymphMark - Lymphoma Subtyping Test

LymphMark (Lymphoma) – We are developing this lymphoma subtyping test as a companion diagnostic for Acerta Pharma and AstraZeneca’s acalabrutinib (Calquence®). In April 2021, we announced that the first patient has been enrolled and randomized in Acerta Pharma’s Phase 3 ESCALADE trial, which uses the investigational LymphMark test to identify patients with untreated diffuse large B-cell lymphoma (DLBCL) who may benefit from Calquence in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy.